Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Precision Therapeutics Amend Co-marketing Deal Again

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 2012 and revised in October.

As amended, Rosetta has granted Precision the co-exclusive rights to market Rosetta's Cancer Origin test in the US with Rosetta, it said in a document filed with the US Securities and Exchange Commission. Precision must use "commercially reasonable efforts" to market and promote the test, which was formerly called miRview mets2.

Rosetta will record all revenues for sales of the test and is responsible for sample collection, processing, and billing.

As amended the deal has an initial term of one year and will be automatically renewed for an additional six-month period.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.